Epigral Ltd 03 Nov 2026 12:00 AM
Epigral Ltd consolidated sales up 5.76% on year in Q3FY2026,
Epigral Ltd share price rallied 8.81% to Rs 951.2 after the company`s net profit tumbled by 34.75% to Rs 65.08 crore, while revenue from operations slightly gained 5.76% to Rs 745.99 crore in Q3FY26 over Q2FY26. The market capitalization of Specialty Chemicals industry group stocks on BSE stood at Rs 5.64 lakh crore, climbing 13.76%. It has marginally improved by 0.04% over last one week and eased lower by 7.04% in last one month while the market capitalization of Epigral Ltd has improved by 5.88% and 14.87% in the same period respectively. Profit before tax (PBT) of Epigral Ltd stood at Rs 87.58 crore in Q3 FY26, jumping 25.74% year-on-year, and tanking 34.51% quarter-on-quarter. EBITDA came in at Rs 130 crore, declining 0.25% YoY and plunging by 25.59% sequentially. Total expenses rose by 14.95% to Rs 654.11 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 469.4 crore, inching up 9.12% YoY, while employee benefits expense was at Rs 33.7 crore, dropping 8.17% YoY. For the TTM ended FY26, revenue from operations surged 32.19% to Rs 2550.13 crore, while net profit soared by 82.62% to Rs 357.69 crore, compared to previous TTM. EBITDA jumped by 48263% to Rs 695.51 crore, and PBT witnessed a strong rise of 86.10% to Rs 541.09 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 440.56 crore in FY26, as against Rs 397.64 crore in FY25. Epigral Ltd plunged by 43.98% in last one year, underperforming the benchmark BSE Sensex which has slipped by 9.87% during the same period.
Epigral Ltd 02 Nov 2026 12:00 AM
Epigral Ltd consolidated sales up 5.76% on year in Q3FY2026,
Epigral Ltd share price softened by 3.25% to Rs 874.15 after the company`s net profit witnessed a sharp fall of 34.75% to Rs 65.08 crore, while revenue from operations improved marginally 5.76% to Rs 745.99 crore in Q3FY26 over Q2FY26. The market capitalization of Specialty Chemicals industry group stocks on BSE stood at Rs 5.61 lakh crore, heading higher 14.14%. It has inched up 0.63% over last one week and edged lower by 7.05% in last one month while the market capitalization of Epigral Ltd has slipped by 1.49% and 20.74% in the same period respectively. Profit before tax (PBT) of Epigral Ltd stood at Rs 87.58 crore in Q3 FY26, jumping 25.74% year-on-year, and nosediving by 34.51% quarter-on-quarter. EBITDA came in at Rs 130 crore, declining 0.25% YoY and tumbling by 25.59% sequentially. Total expenses rose by 14.95% to Rs 654.11 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 469.4 crore, inching up 9.12% YoY, while employee benefits expense was at Rs 33.7 crore, contracting 8.17% YoY. For the TTM ended FY26, revenue from operations witnessed a strong growth of 32.19% to Rs 2550.13 crore, while net profit surged by 82.62% to Rs 357.69 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 48263% to Rs 695.51 crore, and PBT jumped 86.10% to Rs 541.09 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 440.56 crore in FY26, as against Rs 397.64 crore in FY25. Epigral Ltd nosedived by 48.19% in last one year, underperforming the benchmark BSE Sensex which has declined by 11.78% during the same period.
Epigral Ltd 26 Oct 2026 12:00 AM
Epigral Limited’s board will convene November 2 to review financial results,
Epigral Limited will hold a meeting of its Board of Directors on November 2, 2026, to consider and approve the unaudited financial results for the second quarter and half year ended September 30, 2026, along with the Limited Review Report from the statutory auditors.
Epigral Ltd 15 Oct 2026 12:00 AM
Epigral Limited received a certificate from MUFG Intime India for the quarter ending September 30, 2026,
Epigral Limited informed the National Stock Exchange of India Limited and BSE Limited that it received a confirmation certificate from MUFG Intime India Private Limited, formerly Link Intime India Private Limited, for the quarter ended September 30, 2026, pertaining to Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.
Epigral Ltd 28 Sep 2026 12:00 AM
Epigral Limited closes trading window for insiders ahead of financial results release,
Epigral Limited informed the National Stock Exchange of India Limited and BSE Limited that the trading window for equity shares will be closed for insiders, directors, promoters, designated persons, and their immediate relatives from October 1, 2026, until 48 hours after the declaration of the un-audited financial results for the second quarter and half year ended September 30, 2026.
Subscribe for our
newsletter
Open Account Now